Diversify Wealth Management LLC Purchases 10,630 Shares of Zoetis Inc. (NYSE:ZTS)

Diversify Wealth Management LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 72.8% during the fourth quarter, Holdings Channel reports. The firm owned 25,224 shares of the company’s stock after acquiring an additional 10,630 shares during the period. Diversify Wealth Management LLC’s holdings in Zoetis were worth $4,120,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis during the third quarter worth about $33,000. Dunhill Financial LLC raised its position in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Finally, Quarry LP boosted its stake in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS stock opened at $166.01 on Monday. The firm has a 50 day moving average of $170.93 and a 200-day moving average of $179.98. The firm has a market capitalization of $74.90 billion, a P/E ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned $1.36 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.